OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Rhea-AI Summary

OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on developing innovative ocular therapies, announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024. The company specializes in treatments for inflammatory dry eye disease (DED), a multi-billion-dollar market, and neuropathic corneal pain (NCP), an ocular condition without FDA-approved therapy.

OKYO's management will deliver a pre-recorded presentation available on-demand from 7:00 am EDT on the conference day. Interested parties can register for the conference and arrange virtual 1x1 meetings with OKYO's management through H.C. Wainwright representatives.

Positive

• Participation in a significant industry conference, potentially increasing visibility and investor interest
• Focus on multi-billion-dollar market of inflammatory dry eye disease (DED)
• Development of treatment for neuropathic corneal pain (NCP), an unmet medical need without FDA-approved therapy

Negative

• None.

News Market Reaction

-1.98%

1 alert

-1.98% News Effect

On the day this news was published, OKYO declined 1.98%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the company will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, which is being held on Thursday, August 15th.

Management’s pre-recorded company presentation can be accessed on-demand beginning at 7:00 am EDT on the day of the conference.

For additional information, or to register for the conference, please click here. To arrange a virtual 1x1 meeting with OKYO Pharma’s management, please contact your H.C. Wainwright representative.

About OK-101
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing efficacy signals in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment. OK-101 recently showed statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-blind, placebo-controlled trial of OK-101 to treat DED.

About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.

Enquiries:

OKYO Pharma Limited	Gary S. Jacob, Chief Executive Officer	917-497-7560
Business Development & Investor Relations	Paul Spencer	+44 (0)20 7495 2379

FAQ

When is OKYO Pharma participating in the H.C. Wainwright Ophthalmology Conference?

OKYO Pharma is participating in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on Thursday, August 15, 2024.

What are the main therapeutic areas OKYO Pharma (NASDAQ: OKYO) is focusing on?

OKYO Pharma is focusing on developing therapies for inflammatory dry eye disease (DED) and neuropathic corneal pain (NCP).

How can investors access OKYO Pharma's presentation at the H.C. Wainwright conference?

Investors can access OKYO Pharma's pre-recorded presentation on-demand beginning at 7:00 am EDT on the day of the conference, August 15, 2024.

Is there an FDA-approved therapy for neuropathic corneal pain (NCP) that OKYO Pharma is developing?

No, there is currently no FDA-approved therapy for neuropathic corneal pain (NCP), which is why OKYO Pharma is developing a treatment for this condition.